Nasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value

Reuters03-21 04:46

Nasdaq flags Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for sub-$1 bid price and sub-USD 50 million market value

Quince Therapeutics received a Nasdaq notice that its shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days.
The company has until September 14, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.
A separate Nasdaq notice said Quince’s market value of listed securities was below the $50.0 million continued listing requirement for 30 consecutive business days.
Quince has until September 14, 2026 to restore market value of listed securities to at least $50.0 million for at least 10 consecutive business days.
The notices do not trigger immediate delisting, and the stock continues trading on the Nasdaq Global Select Market under the symbol QNCX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117794), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621754563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-21 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621754563","market":"fut","top_or_hot":-1,"title":"Nasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nasdaq flags Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for sub-$1 bid price and sub-USD 50 million market value\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Quince Therapeutics received a Nasdaq notice that its shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days.\n        </li>\n<li>\n          The company has until September 14, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.\n        </li>\n<li>\n          A separate Nasdaq notice said Quince’s market value of listed securities was below the $50.0 million continued listing requirement for 30 consecutive business days.\n        </li>\n<li>\n          Quince has until September 14, 2026 to restore market value of listed securities to at least $50.0 million for at least 10 consecutive business days.\n        </li>\n<li>\n          The notices do not trigger immediate delisting, and the stock continues trading on the Nasdaq Global Select Market under the symbol QNCX.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117794), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-21 04:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nasdaq flags Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for sub-$1 bid price and sub-USD 50 million market value\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Quince Therapeutics received a Nasdaq notice that its shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days.\n        </li>\n<li>\n          The company has until September 14, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.\n        </li>\n<li>\n          A separate Nasdaq notice said Quince’s market value of listed securities was below the $50.0 million continued listing requirement for 30 consecutive business days.\n        </li>\n<li>\n          Quince has until September 14, 2026 to restore market value of listed securities to at least $50.0 million for at least 10 consecutive business days.\n        </li>\n<li>\n          The notices do not trigger immediate delisting, and the stock continues trading on the Nasdaq Global Select Market under the symbol QNCX.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117794), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL9RrCTy:1","article_id":"2621754563","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621754563","pubTimestamp":1774039571,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quince Therapeutics received a Nasdaq notice that its shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days.The company has until September 14, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.A separate Nasdaq notice said Quince’s market value of listed securities was below the $50.0 million continued listing requirement for 30 consecutive business days.Quince has until September 14, 2026 to restore market value of listed securities to at least $50.0 million for at least 10 consecutive business days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this ne","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QNCX":"Quince Therapeutics, Inc."},"translate_title":"纳斯达克标记Quince Therapeutics的投标价格低于1美元，市值低于5000万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"Nasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value\n    \n\n\n          Quince Therapeutics received a Nasdaq notice that its shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days.\n        \n\n          The company has until September 14, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.\n        \n\n          A separate Nasdaq notice said Quince’s market value of listed securities was below the $50.0 million continued listing requirement for 30 consecutive business days.\n        \n\n          Quince has until September 14, 2026 to restore market value of listed securities to at least $50.0 million for at least 10 consecutive business days.\n        \n\n          The notices do not trigger immediate delisting, and the stock continues trading on the Nasdaq Global Select Market under the symbol QNCX.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117794), on March 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621754563","isCrawlerRequest":true}